Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)

被引：0
|
作者：
N. L. Steele
J. A. Plumb
L. Vidal
J. Tjørnelund
P. Knoblauch
P. Buhl-Jensen
R. Molife
R. Brown
J. S. de Bono
T. R. J. Evans
机构：
[1] Beatson West of Scotland Cancer Centre,Centre for Oncology and Applied Pharmacology
[2] University of Glasgow,undefined
[3] Royal Marsden Hospital,undefined
[4] Topotarget,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 67卷
关键词：
Histone deacetylase; Phase-1 trial; Pharmacokinetics; Pharmacodynamics; Bioavailability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：1273 / 1279
页数：6
相关论文
共 50 条
  • [1] Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)
    Steele, N. L.
    Plumb, J. A.
    Vidal, L.
    Tjornelund, J.
    Knoblauch, P.
    Buhl-Jensen, P.
    Molife, R.
    Brown, R.
    de Bono, J. S.
    Evans, T. R. J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (06) : 1273 - 1279
  • [2] Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer
    Qian, Xiaozhong
    Ara, Gulshan
    Mills, Evan
    LaRochelle, William J.
    Lichenstein, Henri S.
    Jeffers, Michael
    INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (06) : 1400 - 1410
  • [3] The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines
    Ma, Brigette B. Y.
    Sung, Fion
    Tao, Qian
    Poon, Fan Fong
    Lui, Vivian W.
    Yeo, Winnie
    Chan, Stephen L.
    Chan, Anthony T. C.
    INVESTIGATIONAL NEW DRUGS, 2010, 28 (02) : 107 - 114
  • [4] The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines
    Brigette B.Y. Ma
    Fion Sung
    Qian Tao
    Fan Fong Poon
    Vivian W. Lui
    Winnie Yeo
    Stephen L. Chan
    Anthony T.C. Chan
    Investigational New Drugs, 2010, 28 : 107 - 114
  • [5] Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)
    Cashen, Amanda
    Juckett, Mark
    Jumonville, Alcee
    Litzow, Mark
    Flynn, P. J.
    Eckardt, John
    LaPlant, Betsy
    Laumann, Kristina
    Erlichman, Charles
    DiPersio, John
    ANNALS OF HEMATOLOGY, 2012, 91 (01) : 33 - 38
  • [6] The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo
    Buckley, Michael T.
    Yoon, Joanne
    Yee, Herman
    Chiriboga, Luis
    Liebes, Leonard
    Ara, Gulshan
    Qian, Xiaozhong
    Bajorin, Dean F.
    Sun, Tung-Tien
    Wu, Xue-Ru
    Osman, Iman
    JOURNAL OF TRANSLATIONAL MEDICINE, 2007, 5 (1)
  • [7] The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo
    Michael T Buckley
    Joanne Yoon
    Herman Yee
    Luis Chiriboga
    Leonard Liebes
    Gulshan Ara
    Xiaozhong Qian
    Dean F Bajorin
    Tung-Tien Sun
    Xue-Ru Wu
    Iman Osman
    Journal of Translational Medicine, 5
  • [8] Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)
    Amanda Cashen
    Mark Juckett
    Alcee Jumonville
    Mark Litzow
    P. J. Flynn
    John Eckardt
    Betsy LaPlant
    Kristina Laumann
    Charles Erlichman
    John DiPersio
    Annals of Hematology, 2012, 91 : 33 - 38
  • [9] Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates
    Warren, Katherine E.
    McCully, Cindy
    Dvinge, Henrik
    Tjornelund, Jette
    Sehested, Maxwell
    Lichenstein, Henri S.
    Balis, Frank M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (03) : 433 - 437
  • [10] Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates
    Katherine E. Warren
    Cindy McCully
    Henrik Dvinge
    Jette Tjørnelund
    Maxwell Sehested
    Henri S. Lichenstein
    Frank M. Balis
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 433 - 437
12345